Medical Devices Examples: From Bandages to Biologics in 2026
Introduction: What Counts as a Medical Device in 2026?
Ask most people to name a medical device, and they will likely picture something simple: an adhesive bandage, a thermometer, or perhaps a wheelchair. Those answers are correct, but they capture only a small part of the picture. In 2026, the category also includes artificial intelligence software that diagnoses eye disease, implants coated with medication, and wound products built from collagen and living cells.
This article begins with the familiar FDA classification examples that most guides cover, then continues into the categories that most “medical devices examples” articles leave out.
The scope of the field is large. The World Health Organization estimates that around 2 million medical devices are available globally, grouped into more than 7,000 generic device groups. In the United States, the FDA has classified approximately 1,700 generic device types and organized them into 16 medical panels.
The sections below move from Class I bandages to Class III pacemakers, then into Software as a Medical Device (SaMD), combination products, 3D-printed implants, and biologic and tissue-engineered wound care. That last category is one of the most complex and least explained areas of modern healthcare innovation.
What Legally Makes Something a “Medical Device”?
In the United States, the definition comes from Section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act. According to the FDA, a device is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease.
The most important part of the definition is what a device does not do. Medical devices do not achieve their primary intended purpose through metabolism or chemical action within the body. That single distinction separates a device from a drug. A bandage protects a wound physically; an antibiotic works by chemically affecting bacteria.
This line becomes important later in the article. Combination products and biologic wound care deliberately blur the boundary between physical, chemical, and biological action, which is why they are harder to classify.
The Familiar Starting Point: FDA’s Three Device Classes
The FDA uses a risk-based system that assigns each generic device type to one of three regulatory classes. The class reflects the level of control needed to provide reasonable assurance of safety and effectiveness. The higher the risk to the patient, the stricter the requirements.
Many readers have encountered this framework before, so the following overview is brief. It serves as a baseline for the newer categories discussed afterward.
Class I: Low-Risk, Everyday Devices
Class I devices present minimal potential for harm and are often simpler in design than Class II or Class III devices. These are the products people handle in homes, clinics, and first-aid kits without much thought.
Common examples include:
- Elastic bandages
- Enema kits
- Tongue depressors
- Handheld surgical instruments, such as basic scalpels and forceps
According to the FDA, 47% of medical devices fall into this category, and 95% of those are exempt from the premarket regulatory process. The figures reflect how common and low-stakes these items are.
Class II: Moderate-Risk Devices That Monitor and Support
Class II devices carry more risk than Class I products and require additional regulatory controls, often including performance standards and premarket notification through the 510(k) pathway.
Common examples include:
- Powered wheelchairs
- Some pregnancy test kits
- Infusion pumps
- Diagnostic imaging equipment
About 43% of medical devices fall into Class II, which makes it one of the core categories of the market. These devices monitor, measure, deliver, and support care across nearly every clinical setting.
Class III: High-Risk, Life-Sustaining Devices
Class III devices usually sustain or support life, are implanted, or present a potential unreasonable risk of illness or injury. They face the most rigorous review, typically through premarket approval (PMA), which requires substantial clinical evidence.
Common examples include:
- Implantable pacemakers
- Breast implants
Only 10% of medical devices fall into Class III, even though these are the highest-stakes products most people will encounter.
This is where most articles on medical device examples end. The sections below cover where much of the current innovation, and much of the regulatory complexity, is found.
Beyond the Checklist: Software as a Medical Device (SaMD)
Not every medical device has a physical form. Software as a Medical Device (SaMD) is software intended for one or more medical purposes that performs those purposes without being part of a hardware medical device. It runs independently on general-purpose computers, smartphones, tablets, or cloud infrastructure.
A widely cited example is LumineticsCore (formerly IDx-DR). In 2018, it became the first FDA-authorized autonomous AI diagnostic SaMD, cleared through the De Novo classification pathway. The software detects diabetic retinopathy, a leading cause of vision loss in people with diabetes, in primary care settings without an eye specialist present. Because screening can take place during a routine visit, more patients can be checked earlier.
That example was part of a broader trend. Industry analysts at MarketsandMarkets project that AI-based devices will lead the technology category of the global medical devices market with a 33.2% share in 2026, with gains expected in diagnostic accuracy, operational efficiency, and personalized care.
SaMD does not fit easily into the traditional Class I, II, and III model that most people associate with physical products. Software has no materials, no moving parts, and nothing implanted. Regulators instead evaluate it based on the risk to the patient and how much the software’s output influences clinical decisions. A program that only displays information carries different risks than one that independently makes a diagnosis.
Other examples of SaMD include:
- AI-powered apps that screen photographs of skin lesions for signs of skin cancer
- Software that analyzes CT, MRI, or X-ray scans to flag possible abnormalities
- Prescription digital therapeutics that deliver structured treatment for mental health conditions
When Drug Meets Device: Combination Products
Some of the most common treatments in modern medicine belong to two regulatory categories at the same time. These are known as combination products.
According to FDA and NIH guidance, a combination product consists of two or more regulated components (drug and device, biologic and device, or drug and biologic) combined into a single entity. The term also covers products labeled for use together when both components are required to achieve the intended effect.
Because these products involve more than one type of technology, the FDA uses a concept called the primary mode of action (PMOA). Regulators identify which component is mainly responsible for the therapeutic effect, then assign the product to a “lead center” for review:
- CDRH (Center for Devices and Radiological Health) if the device component drives the effect
- CDER (Center for Drug Evaluation and Research) if the drug component drives the effect
- CBER (Center for Biologics Evaluation and Research) if the biologic component drives the effect
This step shapes how these products are tested, approved, and monitored, yet it is rarely explained in consumer-oriented content.
Recognizable examples include:
- Drug-eluting stents: Small mesh scaffolds placed inside arteries and coated with medication that helps prevent the vessel from narrowing again (a process called restenosis).
- Transdermal patches: Adhesive patches that deliver medication through the skin over time, such as those used for nicotine replacement or pain management.
- Prefilled drug-delivery syringes: Ready-to-use injectors that combine a measured dose of medication with its delivery mechanism.
Many patients have used a combination product without realizing it. A patch, a stent, or an auto-injector may look like a single item, but each is regulated as both a drug and a device.
The Regulatory Gray Zone: Biologic and Tissue-Engineered Wound Care
General-audience articles on medical devices almost never cover this category, even though it addresses a large and growing medical need.
Chronic wounds affect approximately 1 to 2 percent of the population in developed countries, according to research published through the National Institutes of Health. Prevalence continues to rise because of aging populations and the increasing number of people with diabetes, obesity, and peripheral vascular disease. Common chronic wounds include:
- Diabetic foot ulcers
- Pressure ulcers (bedsores)
- Venous leg ulcers
These wounds often do not respond to standard dressings, which has driven the development of advanced biologic products that are difficult to categorize. As a technical brief from the Centers for Medicare & Medicaid Services notes, the FDA does not refer to any product or class of products as “skin substitutes.” The term is used informally. These products also do not literally replace skin the way a skin graft does; they are applied to wounds to support healing through a range of biological and structural mechanisms.
Why These Products Don’t Fit One Bucket
Depending on origin and composition, the FDA regulates these products under up to four pathways:
- HCT/P designation (human cells, tissues, or cellular and tissue-based products)
- Premarket approval (PMA)
- Humanitarian Use Device designation
- 510(k) clearance, typically for animal-derived or synthetic products
HCT/Ps are defined as human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient. This category includes many amniotic membrane and dermal allograft wound products.
The pathway depends on whether the material is human-derived, animal-derived, or synthetic, and on how it is processed. As a result, two wound products that look similar on a clinic shelf can be regulated in very different ways. One may be treated as a minimally manipulated tissue, while another must go through the same premarket approval required for a pacemaker.
Real-World Examples: Named Products Readers May Recognize
Medical literature cites several established biologic wound dressings and skin substitutes:
- Integra: A dermal regeneration template widely used in burn and reconstructive care
- Apligraf: A bilayered living cell-based product used for venous leg ulcers and diabetic foot ulcers
- Dermagraft: A tissue-engineered product containing human fibroblasts, used for diabetic foot ulcers
- BIOBRANE: A biosynthetic dressing used for burns and partial-thickness wounds
- Oasis: An animal-derived extracellular matrix product
- Transcyte: A tissue-engineered temporary wound covering
- Cryoskin and Myskin: Cell-based products developed to support wound closure
Several of these are tissue-engineered with human- or animal-derived biomolecules, including collagen, glycosaminoglycans, hyaluronic acid, laminin, vitronectin, fibronectin, and keratin. These are the same components that make up the body’s own connective tissue, which is why the products can support the natural healing process instead of only covering the wound.
Regranex Gel (becaplermin 0.01%) is another notable case. It is the only commercial FDA-approved growth-factor-loaded wound treatment for chronic foot ulcers. Because it delivers a recombinant growth factor directly to the wound, it combines elements of biologics, drugs, and wound care.
These products sit in a genuine regulatory gray zone, which is why consumer-facing resources rarely explain them and why specialized knowledge is valuable for anyone working with them.
Another Frontier: 3D-Printed and Patient-Specific Devices
3D printing is a manufacturing method, but it has also created a new type of device: products made for a specific patient instead of mass-produced in standard sizes.
The FDA now recognizes 3D-printed implants and surgical guides within its 510(k) clearance process. In April 2024, the agency cleared the first 3D-printed patient-specific PEEK cranial implant. PEEK is a high-performance polymer with mechanical properties similar to human bone.
Examples of 3D-printed medical devices include:
- Spinal implants with porous structures that encourage tissue growth and integration
- Custom anatomical models that let surgeons rehearse complex procedures
- Surgical guides that help position cuts and implants accurately
- Patient-specific prosthetics shaped to an individual’s anatomy
A growing trend is point-of-care customization, in which devices are designed and sometimes produced within or near the treating facility. These products can match a patient’s anatomy with a level of precision that mass manufacturing cannot achieve.
Why This Spectrum Matters: The Growing Medical Device Market
The examples in this article reflect where the industry is heading. MarketsandMarkets projects that the global medical devices market will grow from roughly $580.79 billion in 2026 to $817.78 billion by 2031, a compound annual growth rate of 7.1%.
Much of that growth comes from the categories covered above. AI and software, combination products, and biologic and regenerative products are among the fastest-expanding segments of medical technology.
Understanding this range has practical value. Patients increasingly receive treatments that combine devices, drugs, and biological materials. Students entering healthcare and engineering fields will work with technologies that do not fit traditional categories. Industry professionals need to understand how classification affects product development, evidence requirements, and adoption.
Conclusion: From Bandages to Biologics
This overview covered the full range of the field. It began with familiar Class I items such as elastic bandages and tongue depressors, moved through Class II infusion pumps and Class III pacemakers, and then covered autonomous AI diagnostics, drug-device combination products, patient-specific 3D-printed implants, and biologic wound care products that do not fit a single regulatory category.
In 2026, “medical device” is a much broader term than most people realize. The boundaries between device, drug, and biologic are increasingly blurred, and in many cases that is intentional: combining technologies often produces better outcomes than any single approach.
For patients, caregivers, students, and industry readers, this understanding provides useful context for modern healthcare. It is most important in the gray-zone categories, such as biologics, tissue-engineered products, and regenerative wound care, where navigating classification, evidence, and clinical use requires specialized expertise.
Explore the Innovation Space With Us
The biologic and regenerative device categories covered in this article are among the most promising areas of modern medicine, and among the most complex. Adiamed aims to help readers understand these technologies clearly, without unnecessary jargon.
Patients, caregivers, students, and industry professionals with questions about tissue-engineered wound care, combination products, or regenerative device innovation are encouraged to reach out to the Adiamed team or explore its additional resources. Readers who want to keep up with this changing field can also subscribe for future content on regulatory developments and emerging medical technologies.
